🚀 VC round data is live in beta, check it out!
Veradermics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Veradermics and similar public comparables like Trevi Therapeutics, Nanobiotix, Guangzhou Innogen Pharma, Immunocore Holdings and more.
Veradermics Overview
About Veradermics
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
Founded
2021
HQ
Employees
19
Website
Sectors
Financials (LTM)
EV
$2B
Veradermics Financials
Veradermics reported last 12-month revenue of — and negative EBITDA of ($96M).
In the same LTM period, Veradermics generated — in gross profit, ($96M) in EBITDA losses, and had net loss of ($81M).
Revenue (LTM)
Veradermics P&L
In the most recent fiscal year, Veradermics reported revenue of — and EBITDA of ($26M).
Veradermics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($96M) | XXX | ($26M) | XXX | XXX | XXX |
| Net Profit | ($81M) | XXX | ($26M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Veradermics Stock Performance
Veradermics has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Veradermics' stock price is $45.85.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | — | XXX | XXX | XXX | $-0.76 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVeradermics Valuation Multiples
Veradermics trades at (16.5x) EV/EBITDA.
Veradermics Financial Valuation Multiples
As of March 28, 2026, Veradermics has market cap of $2B and EV of $2B.
Equity research analysts estimate Veradermics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Veradermics has a P/E ratio of (19.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/EBITDA | (16.5x) | XXX | (61.5x) | XXX | XXX | XXX |
| EV/EBIT | (19.2x) | XXX | (60.4x) | XXX | XXX | XXX |
| P/E | (19.7x) | XXX | (60.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (67.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Veradermics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Veradermics Margins & Growth Rates
Veradermics' revenue in the last fiscal year grew by —.
Veradermics' revenue per employee in the last FY averaged $0.0M.
Veradermics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 34% | XXX | 237% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Veradermics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Trevi Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanobiotix | XXX | XXX | XXX | XXX | XXX | XXX |
| Guangzhou Innogen Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Immunocore Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Agios Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Veradermics M&A Activity
Veradermics acquired XXX companies to date.
Last acquisition by Veradermics was on XXXXXXXX, XXXXX. Veradermics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Veradermics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVeradermics Investment Activity
Veradermics invested in XXX companies to date.
Veradermics made its latest investment on XXXXXXXX, XXXXX. Veradermics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Veradermics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Veradermics
| When was Veradermics founded? | Veradermics was founded in 2021. |
| Where is Veradermics headquartered? | Veradermics is headquartered in United States. |
| How many employees does Veradermics have? | As of today, Veradermics has over 19 employees. |
| Is Veradermics publicly listed? | Yes, Veradermics is a public company listed on NYSE. |
| What is the stock symbol of Veradermics? | Veradermics trades under MANE ticker. |
| When did Veradermics go public? | Veradermics went public in 2026. |
| Who are competitors of Veradermics? | Veradermics main competitors are Trevi Therapeutics, Nanobiotix, Guangzhou Innogen Pharma, Immunocore Holdings. |
| What is the current market cap of Veradermics? | Veradermics' current market cap is $2B. |
| Is Veradermics profitable? | No, Veradermics is not profitable. |
| What is the current EBITDA of Veradermics? | Veradermics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Veradermics? | Current EBITDA multiple of Veradermics is (16.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.